We’re nearing the start of the holiday season — in fact, there’s a good chance some of your neighbors already have lights and decorations already up. For many Americans, this time of year is marked by ...

A phase 2 trial has linked Blueprint Medicines’ avapritinib to statistically significant improvements in the symptoms of patients with indolent systemic mastocytosis (SM). The results tee Blueprint up ...

Real-world analysis shows BluePrint® identifies chemotherapy-sensitive Basal-type tumors among MammaPrint® High Risk HR+ HER2- breast cancers, supporting more personalized treatment strategies IRVINE, ...

Blueprint Medicines Corporation BPMC announced that the FDA placed a partial clinical hold on the phase I/II study of pipeline candidate BLU-222. The company is developing investigational inhibitor, ...

The FDA has placed a partial clinical hold on Blueprint Medicines Corporation's (NASDAQ: BPMC) Phase 1/2 VELA trial of BLU-222 due to visual adverse events (AEs) observed in a limited number of ...

A study led by researchers at the University of Oxford, working closely with colleagues from Duurzame Zuivelketen (DZK), among others, has developed a framework to help agricultural sectors better ...

As a young man, Tom Cathey, 72, had been an Air Force pilot. For decades he worked as a forester, overseeing plots of timberland. A few years before he retired, a nurse practitioner found a lump in ...

Blueprint Medicines Corporation BPMC announced top-line data from a phase I/II study on its investigational precision therapy pralsetinib, which is being developed for addressing previously-treated ...

Richard Stern is director of the Grover M. Hermann Center for the Federal Budget at The Heritage Foundation. Matthew Dickerson is the director of the Grover M. Hermann Center for the Federal Budget at ...

College is a whole different world compared to high school. The freedom is greater, but so are the stakes. Deadlines matter more. Exams are harder. And no one is there to remind you to turn things in.

IRVINE, Calif. & AMSTERDAM--(BUSINESS WIRE)--Agendia®, Inc., today announced that new data from its ongoing FLEX Study will be presented at the upcoming ESMO Breast Cancer 2025 congress taking place ...